Showing results (311-320 of 360) with videos related to
Sort By:
Pageof 36
Journal of Radiation Research|July 31, 2007
Low-dose of ionizing radiation enhances cell proliferation via transient ERK1/2 and p38 activation in normal human lung fibroblastsCha Soon Kim, Jin-Mo Kim, Seon Young Nam, et al.International Journal of Radiation Oncology, Biology, Physics|March 31, 2016
Site-Specific Phosphorylation of Ikaros Induced by Low-Dose Ionizing Radiation Regulates Cell Cycle Progression of B Lymphoblast Through CK2 and AKT ActivationSeong-Jun Cho, Hana Kang, Min Young Kim, et al.Antiviral Research|December 22, 2019
Structure-activity relationships of fluorene compounds inhibiting HCV variantsHee Sun Kim, Youngsu You, Jaegon Mun, et al.Carcinogenesis|June 16, 2006
Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancerKyong-Ah Yoon, Bin Hwangbo, Il-Jin Kim, et al.Journal of Radiation Research|August 24, 2012
Augmentation of natural cytotoxicity by chronic low-dose ionizing radiation in murine natural killer cells primed by IL-2Chung Hee Sonn, Jong Rip Choi, Tae-Jin Kim, et al.Free Radical Research|May 23, 2007
Inhibitory effects of glycitein on hydrogen peroxide induced cell damage by scavenging reactive oxygen species and inhibiting c-Jun N-terminal kinaseKyoung Ah Kang, Rui Zhang, Mei Jing Piao, et al.Bioorganic & Medicinal Chemistry|November 13, 2007
Protective effect of irisolidone, a metabolite of kakkalide, against hydrogen peroxide induced cell damage via antioxidant effectKyoung Ah Kang, Rui Zhang, Mei Jing Piao, et al.Acta Haematologica|November 5, 2015
Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual DiseaseHo-Young Yhim, Na-Ri Lee, Eun-Kee Song, et al.International Journal of Cancer|July 30, 2005
Oh8dG induces G1 arrest in a human acute leukemia cell line by upregulating P21 and blocking the RAS to ERK signaling pathwayJin Won Hyun, Sun Hee Yoon, Younsil Yu, et al.Leukemia Research|March 9, 2012
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular responseHo-Young Yhim, Na-Ri Lee, Eun-Kee Song, et al.Pageof 36